How to Get Dayvigo (Lemborexant) in Montana

What Is Dayvigo and Why Do Montana Patients Ask About It

Dayvigo is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for the treatment of insomnia in adults. It works by blocking orexin receptors OX1R and OX2R, suppressing the wake-promoting signals that keep people awake when they want to sleep. Unlike older sedative-hypnotics, it does not broadly depress the central nervous system.

The key SUNRISE-1 randomized controlled trial enrolled 1,006 adults with insomnia disorder and tested lemborexant 5 mg and 10 mg against placebo over 30 nights. Both doses produced statistically significant reductions in subjective sleep onset latency and wake after sleep onset compared with placebo (P<0.001 for both doses) [1]. A second key trial, SUNRISE-2, evaluated 949 participants over 12 months and demonstrated sustained efficacy with no evidence of rebound insomnia upon discontinuation [2].

Interest in Dayvigo has grown across Montana partly because older agents such as zolpidem carry higher fall and next-morning impairment risk in rural patients who drive long distances. The 2023 American Academy of Sleep Medicine (AASM) Clinical Practice Guideline on pharmacologic treatment of chronic insomnia states: "We suggest dual orexin receptor antagonists over benzodiazepine receptor agonists given their more favorable safety profile for long-term use" [3]. That clinical context explains why both patients and prescribers in Montana are seeking access to this medication class.

Lemborexant carries a half-life of approximately 17 to 19 hours [4]. The FDA label cautions against use with strong CYP3A4 inhibitors, and prescribers should screen for sleep apnea and narcolepsy before initiation [4].

Montana Telehealth Rules for Schedule IV Prescriptions

Montana law allows telehealth prescribing of Schedule IV controlled substances, which includes lemborexant. The requirement is a valid prescriber-patient relationship established through a synchronous audio-video encounter before the first prescription is written.

Montana Code Annotated section 37-3-341 defines a valid prescriber-patient relationship for telehealth purposes. The prescriber must conduct a real-time examination sufficient to establish a diagnosis, review the patient's history, and document medical necessity. Text-only or asynchronous-only encounters do not satisfy this standard for a Schedule IV substance.

The DEA's 2023 Special Registration for Telemedicine framework updated federal guidance on controlled substance prescribing via telehealth [5]. Under that framework, Montana prescribers using telehealth must comply with both federal DEA rules and Montana Board of Medical Examiners standards. A prescriber physically located outside Montana must hold a Montana medical license or qualify under Montana's expedited licensure pathway for telemedicine providers.

Telehealth platforms that operate in Montana and specialize in sleep medicine or hormone health are equipped to handle this workflow. A standard first telehealth visit for insomnia runs 20 to 30 minutes and covers sleep history, the Insomnia Severity Index (ISI) score, current medications for drug interactions, and a brief mental health screen. The prescriber documents findings in a SOAP note and, if appropriate, sends the prescription electronically to the patient's preferred Montana pharmacy.

Follow-up visits for Schedule IV renewals are typically required every 30 to 90 days depending on the prescriber's clinical judgment and Montana DEA compliance standards.

Who Can Prescribe Dayvigo in Montana

Any of the following provider types may legally prescribe lemborexant in Montana, provided they hold an active Montana license with Schedule IV DEA registration.

Medical doctors (MDs) and doctors of osteopathic medicine (DOs) have full prescriptive authority in Montana. Advanced practice registered nurses (APRNs) and certified nurse practitioners (CNPs) in Montana may prescribe Schedule IV controlled substances independently once they have completed a collaborative practice agreement requirement, which was removed under Montana Senate Bill 151 (2023). Physician assistants (PAs) may prescribe Schedule IV substances under a supervision agreement with a licensed Montana physician.

The AASM recommends that any clinician prescribing a DORA perform a structured sleep history including assessment for obstructive sleep apnea, because co-existing untreated apnea can worsen outcomes [3]. Screening tools such as the STOP-BANG questionnaire (score 0 to 8; score 3 or higher indicates high apnea risk) are commonly used in telehealth intake forms [6].

Primary care providers in Montana write the majority of insomnia prescriptions statewide, but sleep medicine specialists and telehealth insomnia clinics are the fastest-growing access point. Rural Montana counties, including Petroleum, Carter, and Wibaux, have fewer than one primary care provider per 2,000 residents, making telehealth the practical first point of contact for many patients seeking a Dayvigo prescription [7].

Step-by-Step: Getting a Dayvigo Prescription in Montana

The process from first contact to first dose involves five discrete steps.

Step 1. Choose a prescriber or telehealth platform. Look for a Montana-licensed MD, DO, NP, or PA with DEA Schedule IV authority. Telehealth platforms serving Montana should display the prescriber's Montana license number at intake. The Montana Board of Medical Examiners license verification tool is publicly available at mt.gov.

Step 2. Complete the intake assessment. Most telehealth platforms issue a pre-visit questionnaire covering sleep history, ISI score, current medications, alcohol and substance use, and prior insomnia treatments tried. Documenting prior use of cognitive behavioral therapy for insomnia (CBT-I) is clinically relevant because AASM guidelines recommend CBT-I as first-line therapy before or alongside pharmacotherapy [3].

Step 3. Attend the synchronous video visit. The prescriber reviews your intake data, examines relevant systems, discusses risks of the 5 mg versus 10 mg dose, and addresses contraindications. Contraindications include narcolepsy, severe hepatic impairment, and concomitant use of strong CYP3A4 inhibitors such as clarithromycin or ketoconazole [4].

Step 4. Receive the electronic prescription. In Montana, controlled substance prescriptions may be transmitted electronically (e-prescribing) to a licensed in-state pharmacy. The prescription is valid for six months from the date written for Schedule IV substances under federal law, though Montana pharmacies may apply shorter dispensing windows.

Step 5. Fill at a Montana pharmacy. Most chain pharmacies (Walgreens, Walmart, Albertsons) and independent pharmacies in Montana can stock or order Dayvigo within 24 to 72 hours. If the brand is unavailable, a 503A compounding pharmacy in Montana may prepare lemborexant in oral tablet form under physician order, though compounded versions are not FDA-approved and carry different quality assurance standards.

Labs and Clinical Tests Before Starting Dayvigo

No mandatory laboratory panel is required before initiating lemborexant, but several assessments improve prescribing safety.

A baseline liver function panel (ALT, AST, bilirubin, albumin) is clinically appropriate because lemborexant is primarily metabolized by CYP3A4 in the liver, and the FDA label lists moderate-to-severe hepatic impairment as a contraindication to the 10 mg dose [4]. Patients with moderate hepatic impairment should not exceed 5 mg nightly.

A complete medication reconciliation is more important than blood work. Drugs that inhibit CYP3A4 raise lemborexant plasma concentrations substantially. The FDA label notes that co-administration with itraconazole (a strong CYP3A4 inhibitor) increased lemborexant area-under-the-curve (AUC) by approximately 4-fold [4]. Strong CYP3A4 inducers such as rifampin reduce efficacy; the label advises avoiding lemborexant with strong or moderate CYP3A4 inducers entirely.

Thyroid-stimulating hormone (TSH) testing is worth considering in new-onset insomnia because hyperthyroidism mimics primary insomnia. The American Thyroid Association recommends TSH as the single best screening test for thyroid dysfunction [8]. A serum ferritin may be drawn when restless legs syndrome cannot be excluded, since ferritin below 75 mcg/L is associated with restless legs in clinical guidelines [9].

Sleep study referral (polysomnography or home sleep apnea test) is indicated when STOP-BANG score is 3 or higher, the Epworth Sleepiness Scale score exceeds 10 despite reported insomnia, or the prescriber suspects upper airway obstruction. Lemborexant and other orexin antagonists may theoretically worsen respiratory effort during sleep in patients with moderate-to-severe obstructive sleep apnea [4].

Prior Authorization in Montana: What Documentation You Need

Montana Medicaid does not cover Dayvigo as of 2025. Most commercial insurers in Montana require prior authorization (PA) before dispensing lemborexant.

A standard PA request for lemborexant in Montana includes the following documentation. First, the clinical diagnosis: ICD-10-CM code G47.00 (insomnia, unspecified) or G47.09 (other insomnia). Second, evidence of step therapy: most Montana commercial plans require documented failure of at least one generic sedative-hypnotic, typically zolpidem (brand Ambien, available generically since 2007) or eszopiclone (brand Lunesta, generic available), for a minimum of 30 days. Third, documentation of CBT-I trial or patient ineligibility for CBT-I. Fourth, prescriber attestation of the clinical necessity for a DORA over a benzodiazepine receptor agonist, citing safety rationale.

PA approvals typically take 1 to 5 business days for standard review and 24 to 72 hours for expedited review if the prescriber documents urgent clinical need. Appeals for initial denials are permitted under Montana insurance law; the Montana Commissioner of Securities and Insurance requires insurers to respond to first-level appeals within 30 days.

Cash-pay pricing for Dayvigo without insurance runs approximately $400 to $500 per 30-tablet supply at Montana pharmacies as of 2025. Eisai offers the Dayvigo Savings Card for commercially insured patients, reducing out-of-pocket cost to as low as $15 per fill for eligible patients. Uninsured or underinsured Montana residents may apply to Eisai's patient assistance program at eisai.com.

Montana Pharmacy Access: Chain, Independent, and 503A Compounding

Dayvigo is commercially available as 5 mg and 10 mg oral tablets packaged in 30-count bottles. Montana has approximately 220 licensed retail pharmacies according to the Montana Board of Pharmacy, with the highest concentration in Billings, Missoula, Great Falls, and Bozeman [10].

Rural Montana pharmacies may need 24 to 72 hours to obtain Dayvigo from their drug wholesaler if it is not in standing stock. Patients in small communities should call ahead or ask the prescriber to fax or electronically transmit the prescription a day before the patient expects to pick it up.

Mail-order pharmacies licensed in Montana and accredited by NABP (the National Association of Boards of Pharmacy) may dispense Schedule IV prescriptions by mail under Montana law. A standard mail delivery timeline from a NABP-accredited mail pharmacy to Montana addresses runs 3 to 5 business days via USPS Priority or UPS Ground.

Licensed 503A compounding pharmacies in Montana may prepare lemborexant in oral tablet or capsule form for an individual patient under a valid prescription. 503A pharmacies operate under state Board of Pharmacy oversight and must meet USP Chapter 795 standards for non-sterile compounding [11]. The FDA does not approve compounded drug formulations, so efficacy and bioavailability data from SUNRISE-1 and SUNRISE-2 do not apply directly to compounded lemborexant products.

Transferring a Dayvigo prescription from another state to Montana is permissible for Schedule IV substances under federal law, with two restrictions: the prescription must not have been previously filled (a partially filled Schedule IV prescription may be transferred once under 21 CFR 1306.25), and the receiving Montana pharmacy must verify the prescriber holds an active DEA registration.

Dosing, Administration, and What to Expect in the First Weeks

The FDA-approved starting dose for most adults is lemborexant 5 mg taken orally within 30 minutes of intended bedtime, on nights when at least 7 hours remain for sleep [4]. The dose may be increased to 10 mg if 5 mg is tolerated but insufficiently effective; 10 mg is the maximum approved dose.

Older adults (age 65 and older) should start at 5 mg and generally not exceed 5 mg because of higher peak plasma concentrations seen in pharmacokinetic studies [4]. Patients with moderate hepatic impairment should not exceed 5 mg. The drug should not be taken with or shortly after a high-fat, high-calorie meal because food delays time to peak concentration (Tmax) by approximately 2 hours, potentially reducing onset of sleep benefit on the night of dosing.

SUNRISE-1 data showed that lemborexant 10 mg reduced subjective sleep onset latency by a mean of 18.3 minutes versus 5.4 minutes for placebo at month 1 [1]. Wake after sleep onset improved by a mean of 25.8 minutes with 10 mg versus 8.0 minutes with placebo [1]. These effect sizes appear clinically meaningful for patients whose chief complaint is difficulty staying asleep in the second half of the night.

Most patients report feeling fully alert within 30 to 60 minutes of waking. Next-morning somnolence was reported by 10% of patients on 10 mg versus 1% on placebo in SUNRISE-1 [1]. Patients should avoid driving or operating heavy machinery until they know how the drug affects their morning alertness, particularly during the first two weeks of treatment.

Discontinuation of lemborexant in SUNRISE-2 did not produce rebound insomnia or withdrawal symptoms at rates exceeding placebo at the study endpoint [2]. This distinguishes it from benzodiazepines and some Z-drugs, where abrupt discontinuation frequently worsens sleep for one to two weeks.

Drug Interactions Relevant to Montana Patients

Montana's rural workforce includes agricultural workers and miners who may use medications with clinically significant CYP3A4 effects. Three interaction categories deserve specific attention.

First, opioid co-prescription: lemborexant combined with opioids, benzodiazepines, or other CNS depressants carries an additive risk for respiratory depression. The FDA label includes a boxed warning noting that combining CNS depressants increases risk of complex sleep behaviors and respiratory events [4]. Montana's opioid prescribing rate remains above the national median according to CDC surveillance data [12], making this interaction clinically common in the state.

Second, alcohol: even moderate alcohol consumption on the same evening as lemborexant produces additive CNS depression. Patients should be counseled that a single standard drink taken with the 10 mg dose may produce next-morning impairment equivalent to a blood-alcohol concentration of 0.05 g/dL based on pharmacokinetic modeling [4].

Third, antifungal agents: fluconazole (widely used in Montana agricultural settings for candidiasis) is a moderate CYP3A4 inhibitor. Co-administration with lemborexant 10 mg may increase AUC meaningfully; the FDA label recommends limiting lemborexant to 5 mg when used with moderate CYP3A4 inhibitors and avoiding strong inhibitors entirely [4].

Comparing Lemborexant to Other Insomnia Options Available in Montana

Dayvigo competes with suvorexant (Belsomra, Merck), zolpidem (generic, Ambien), eszopiclone (generic, Lunesta), and doxepin 3 mg/6 mg (Silenor). Each agent has a distinct mechanism and risk profile.

A 2022 network meta-analysis published in The Lancet evaluated 30 insomnia medications across 154 randomized trials (N=44,089 participants) and found that lemborexant ranked among the top agents for sleep efficiency at both short-term (four weeks) and long-term (three months or more) time points [13]. The same analysis found lemborexant had a more favorable next-day functioning profile compared with benzodiazepines and non-benzodiazepine sedative-hypnotics.

Suvorexant 20 mg and lemborexant 10 mg are the two FDA-approved DORAs. Head-to-head data from the SUNRISE-2 extension showed lemborexant 10 mg outperformed suvorexant 20 mg on objective sleep onset latency (measured by polysomnography) at month 6 [2]. Suvorexant is similarly Schedule IV and requires the same prior authorization workflow in Montana.

Zolpidem immediate-release remains the most dispensed sleep medication in Montana pharmacies. At equivalent sedating doses, zolpidem carries a higher risk of complex sleep behaviors (sleepwalking, sleep-driving) compared with lemborexant [14]. The FDA issued a boxed warning on zolpidem and eszopiclone for complex sleep behaviors in 2019 [14].

Doxepin 3 mg and 6 mg are approved specifically for sleep maintenance insomnia and are not Schedule IV substances, making them easier to prescribe via telehealth without DEA Schedule IV registration requirements. They are a useful alternative for patients who cannot obtain a DORA due to insurance restrictions.

Renewing Your Dayvigo Prescription in Montana

Schedule IV prescriptions in Montana may be refilled up to five times within six months of the original prescribing date under 21 CFR 1306.22. After six months or five refills (whichever comes first), a new prescription from the prescriber is required.

Telehealth follow-up for lemborexant renewal typically involves a brief 10 to 15-minute visit where the prescriber reassesses sleep quality using the ISI (a validated 7-item questionnaire scored 0 to 28; scores above 14 indicate moderate-to-severe insomnia), reviews adverse effects, checks for new drug interactions, and confirms ongoing clinical need [15].

Prescribers who follow AASM guidance reassess the need for continued pharmacotherapy at each renewal, because cognitive behavioral therapy for insomnia (CBT-I) remains effective long-term without the ongoing medication exposure. Digital CBT-I programs such as Sleepio and Somryst (FDA-cleared) are accessible to Montana residents via internet and may be recommended alongside or instead of pharmacotherapy for appropriate patients.

Patients who move from Montana or travel frequently should confirm that their receiving pharmacy is NABP-accredited and that the controlled substance laws of the destination state permit Schedule IV mail transfer from Montana. Not all states treat Schedule IV transfers identically.